Emerald Mutual Fund Advisers Trust Celldex Therapeutics, Inc. Transaction History
Emerald Mutual Fund Advisers Trust
- $1.77 Billion
- Q3 2024
A detailed history of Emerald Mutual Fund Advisers Trust transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Emerald Mutual Fund Advisers Trust holds 243,795 shares of CLDX stock, worth $5.74 Million. This represents 0.47% of its overall portfolio holdings.
Number of Shares
243,795
Previous 126,963
92.02%
Holding current value
$5.74 Million
Previous $4.7 Million
76.27%
% of portfolio
0.47%
Previous 0.27%
Shares
2 transactions
Others Institutions Holding CLDX
# of Institutions
207Shares Held
67.3MCall Options Held
1.69MPut Options Held
980K-
Wellington Management Group LLP Boston, MA9.24MShares$218 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$110 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$91.1 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.46MShares$81.5 Million9.64% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$78.5 Million1.99% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.1B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...